The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice
Study Type
OBSERVATIONAL
Enrollment
713
Overall severity of the clinical picture rated on a 4-point scale
Time frame: after 3 and 6 weeks
Changes in dyspnea and/or asthma attacks rated on a 4-point scale
Time frame: after 3 and 6 weeks
Number of dyspnea episodes rated on a 4-point scale
Time frame: after 3 and 6 weeks
Number of awakenings due to night-time dyspnea rated on a 4-point scale
Time frame: after 3 and 6 weeks
Assessment of morning coughing with expectoration rated on a 4-point scale
Time frame: after 3 and 6 weeks
Assessment of tolerability on a 4-point scale
Time frame: after 3 and 6 weeks
Number of patients with adverse drug reactions
Time frame: up to 6 weeks
Changes in pathological auscultation findings rated on a 3-point scale
Time frame: after 3 and 6 weeks
Changes in concomitant medication
Time frame: up to 6 weeks
Assessment of efficacy on a 4-point scale
Time frame: after 3 and 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.